美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · TEM近 30 天 7 則 · 第 1 / 1 頁
- Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?
- Tempus AI Stock Surges as Revenue Optimism Boosts Winning Streak
- Piper Sandler Lifts Tempus AI to Overweight at $76
- Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
- Tempus AI (TEM) Stock Looks Fully Valued After Its 55% Jump
- Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis Deal - What's Changed
- Has Tempus AI (TEM) Run Too Far Ahead Of Its Valuation Narrative?
- How Investors May Respond To Tempus AI (TEM) Q2 Profit Return, Outlook Hike, Personalis Deal
- Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates
- Tempus makes $1.5B bet to corner cancer-test market
- Short Report: Tempus AI short interest at record high
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。